Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

被引：11

作者：

Anderson, Rose ^{[1
]}

Hayes, Jennifer ^{[1
]}

Stephens, Jeffrey W. ^{[1
,2
]}

机构：

[1] ABM Univ Hlth Board, Morriston Hosp, Dept Diabet & Endocrinol, Swansea, W Glam, Wales

[2] Swansea Univ, Inst Life Sci, Diabet Res Grp, Swansea, W Glam, Wales

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2016年 / 12卷 / 04期

关键词：

saxagliptin; glucagon-like peptide 1; DPP-4; SAVOR-TIMI; 53; ADD-ON THERAPY; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; CARDIOVASCULAR OUTCOMES; RENAL IMPAIRMENT; GLYCEMIC CONTROL; IV INHIBITOR; EFFICACY; SAFETY; METFORMIN;

D O I：

10.1517/17425255.2016.1154044

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Introduction: Dipeptide peptidase-4 (DPP-4) inhibitors such as saxagliptin are established and efficacious oral therapies in the management of type 2 diabetes. These agents have the potential to confer significant benefits in glycemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes. Areas covered: This review examines the pharmacokinetics, efficacy and tolerability of saxagliptin for the management of type 2 diabetes. Expert opinion: Saxagliptin is routinely used in the management of type 2 diabetes as monotherapy, and in combination with other oral agents and insulin. Robust clinical trials have shown consistent improvements in glycated hemoglobin, fasting and postprandial glucose levels, with few adverse effects. The agent is well tolerated with low rates of hypoglycemia in the absence of insulin or sulphonylurea therapy.

引用

页码：467 / 473

页数：7

共 47 条

[1] Saxagliptin overview: special focus on safety and adverse effects [J].

Ali, Shamsa ;

Fonseca, Vivian .

EXPERT OPINION ON DRUG SAFETY, 2013, 12 (01) :103-109

[2] Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].

Augeri, DJ ;

Robl, JA ;

Betebenner, DA ;

Magnin, DR ;

Khanna, A ;

Robertson, JG ;

Wang, AY ;

Simpkins, LM ;

Taunk, P ;

Huang, Q ;

Han, SP ;

Abboa-Offei, B ;

Cap, M ;

Xin, L ;

Tao, L ;

Tozzo, E ;

Welzel, GE ;

Egan, DM ;

Marcinkeviciene, J ;

Chang, SY ;

Biller, SA ;

Kirby, MS ;

Parker, RA ;

Hamann, LG .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037

[3] Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy [J].

Barnett, Anthony H. ;

Charbonnel, Bernard ;

Li, Jia ;

Donovan, Mark ;

Fleming, Douglas ;

Iqbal, Nayyar .

CLINICAL DRUG INVESTIGATION, 2013, 33 (10) :707-717

[4] Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin [J].

Barnett, Anthony H. ;

Charbonnel, Bernard ;

Donovan, Mark ;

Fleming, Douglas ;

Chen, Roland .

CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) :513-523

[5] Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin [J].

Boulton, David W. ;

Li, Li ;

Frevert, Ernst U. ;

Tang, Angela ;

Castaneda, Lorna ;

Vachharajani, Nimish N. ;

Kornhauser, David M. ;

Patel, Chirag G. .

CLINICAL PHARMACOKINETICS, 2011, 50 (04) :253-265

[6] Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy [J].

Bryzinski, Brian ;

Allen, Elsie ;

Cook, William ;

Hirshberg, Boaz .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) :887-893

[7] Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks [J].

Chacra, Antonio R. ;

Tan, Gerry H. ;

Ravichandran, Shoba ;

List, James ;

Chen, Roland .

DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (02) :150-159

[8] Saxagliptin Dipeptidyl Peptidase IV Inhibitor Antidiabetic Agent [J].

Cole, P. ;

Serradell, N. ;

Bolos, J. ;

Castaner, R. .

DRUGS OF THE FUTURE, 2008, 33 (07) :577-586

[9] Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies [J].

Davidson, Jaime A. .

JOURNAL OF MANAGED CARE PHARMACY, 2014, 20 (02) :120-129

[10] The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone [J].

DeFronzo, Ralph A. ;

Hissa, Miguel N. ;

Garber, Alan J. ;

Gross, Jorge Luiz ;

Duan, Raina Yuyan ;

Ravichandran, Shoba ;

Chen, Roland S. .

DIABETES CARE, 2009, 32 (09) :1649-1655

← 1 2 3 4 5 →